Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Sotatercept’s win in pulmonary arterial hypertension positions Acceleron for a battle against the leaders in this crowded space.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
Cardiovascular safety is great news, but the main problem with the Eisai drug is that it simply doesn’t work as monotherapy.
Featuring at the European Society of Cardiology meeting, which kicks off this weekend in Munich, are results with tafamidis, Xarelto and fish oil supplements.